Acotinib/Acalatinib price list

Acalabrutinib/Acalabrutinib is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior treatment; it has been designated as an orphan drug for this purpose by the U.S. Food and Drug Administration (FDA). At the same time, acotinib is also suitable for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Experts generally recommend BTK inhibitors, including acotinib and ibrutinib, as first-line treatment options for patients with symptomatic or progressive CLL.

Acotinib belongs to a class of drugs calledBTK (Bruton's tyrosine kinase) inhibitors. BTK is a tyrosine kinase that plays an important role in the B cell receptor signaling pathway. In certain types of leukemia and lymphoma, this signaling pathway is abnormally activated, leading to excessive proliferation and survival of cancer cells. Acotinib works by selectively inhibiting the activity of BTK. It binds to BTK, preventing its participation in signaling pathways and inhibiting the growth and spread of cancer cells. This inhibitory effect helps reduce symptoms caused by leukemia and lymphoma and slows the progression of the disease.

The original drug of acotinib has been launched in China and has also been included in the medical insurance system. The common drug specifications are100mg, 8 tablets and 7 tablets. However, its price is not cheap, with each box selling for about 40,000 yuan. In overseas markets, the price of this drug is as high as more than 10,000 US dollars, which is indeed very expensive. But fortunately, there are generic versions of acotinib available on the market, which are basically the same ingredients as the original drug. For example, the price of 100mg*60 tablets of medicine produced by a pharmaceutical factory in Laos is relatively affordable, about more than 3,000 yuan, but the price may be affected by exchange rate changes.